2006 - UZ Leuven

More documents

Recommendations

Info

TOMBAL B., IVERSEN P., VAN POPPEL H., TAMMELA T.L., DE LAROSETTE J.J., JOHANSSON J.E., PERSSON B.E., JENSEN J.K.,OLESEN T.K.: Determining the dose of degarelix for effective therapy ofprostate cancer patients as investigated by the degarelix study groups.Annals of Oncology, 2006; Volume 17, Suppl.9: (461P).Introduction: Degarelix is a gonadotropin-releasing hormone (GnRH)blocker with an immediate onset of action that produces fast, profoundand sustained suppression of serum testosterone (T) levels, without Tsurge.Objective: International, multicentre, phase II studies were performedto determine the initiation dose (studies 1 and 2) and maintenancedose (study 2) of degarelix for hormonal therapy of prostate cancer(CaP).Methods: Both studies involved patients with histologically confirmedCaP, PSA levels ≥ 2ng/mL, and who were candidates for hormonaltherapy. In study 1, patients (n=172) were randomised to receivedegarelix as a single dose of 120-360 mg. In study 2, following aninitiation dose of 200 or 240 mg, patients (n=187) received monthlymaintenance doses of 80, 120 or 160 mg. Response was defined aspercentage of patients with T ≤ 0.5 mg/mL.Results: In study 1, all doses produced fast (by day 3) and profoundsuppression of T levels to ≤ 0.5 mg/mL and suppression wassustained up to at least day 28. Responses at both time-points (days3 and 28) were dose dependent. No T surge was observed. At a doseof 240 mg, 96% of patients achieved T suppression to ≤ 0.5 mg/mL atday 28 and PSA decreased to 25% of the baseline level at this timepoint.In study 2, 95% (240 mg group) of patients achieved Tsuppression to ≤ 0.5 mg/mL at day 28. For patients with T ≤ 0.5mg/mL at day 28 (n = 168) response rates at one year increased withmaintenance dose from 92% (80 mg), to 96% (120 mg) and 100%(160 mg). Median percentage reductions in PSA levels for theresponders were similar for all three maintenance doses and were ≥95% from week 12 onwards.Conclusion: Degarelix at an initiation dose of 240 mg induced fast andprofound T suppression to ≤ 0.5 mg/mL in 96% of patients within 3days of administration, without T surge. Monthly maintenance therapywith 160 mg produced sustained T suppression in 100% of patients.Degarelix induced fast, profound and sustained reduction of PSA andwas well tolerated. This dose regimen has been referred to a phase IIIprogram.154
VAN CALSTEREN K., VAN MENSEL K., JONIAU S., OYEN R., HANSSENSM., AMANT F., VAN POPPEL H.: Urachal carcinoma during pregnancy.Urology, 2006; 67: 1290-1291.We report a case of Stage T4aN2M0 urachal carcinoma that wasdiagnosed early in pregnancy. Because positive pelvic lymph nodesand uterine involvement were present, surgical resection, includinghysterectomy with termination of the pregnancy, and postoperativeradiotherapy were performed. The treatment options, which largelydepend on the duration of the pregnancy, the tumor stage, and thepatient’s desire to continue the pregnancy, are discussed.VAN DER KWAST T., BOLLA M., VAN POPPEL H., VEKEMANS K., VANCANGH P., SCHRODER F., DE REIJKE T., DAPOZZA L., BOSSET J.F.,COLLETTE L.: Impact of pathological review of radical prostatectomyspecimens on prognosis and predicted benefit from immediatepostoperative irradiation for high-risk patients (EORTC 22911). Eur.Urol. Suppl., 2006; 5(2): 205 (729).Introduction & Objectives: Patients with prostate cancer extending intosurgical margins and/or extension beyond the capsule have anincreased risk of local failure. As a part of EORTC trial 2911 apathological review of prostatectomy specimens was performed toassess predictors of biochemical recurrence.Material & Methods: After radical prostatectomy 503 patients wererandomly assigned to a control arm and 502 to immediatepostoperative radiotherapy. All eligible patients had pN0M0 diseaseand local pathology showed pT3a/b disease and/or positive surgicalmargins. A total of 552 prostatectomy specimens (280 control arm,272 test arm) of 12 major centres was reviewed and the localpathology in relation to biochemical recurrence by treatment arm wasassessed by logrank test for heterogeneity (α=0.05).Results: Agreement of local pathologists and review pathologist washigh (Kappa 0.83) for seminal vesicle involvement, but low forextracapsular extension and margin status (kappa 0.33 and 0.45respectively). The overall agreement for extracapsular extension andmargin status was 57.5 and 69.4% respectively. More tumours wereconsidered organ confined by the reviewer and causes fordiscrepancies were e.g. the automatic assignment by localpathologists of surgical margin positive cases of pT3 category. Reviewpathology of surgical margins was a stronger predictor of biochemicalrecurrence than local pathology (HR=2.16, P=0.0002 versus HR=1.08p>0.1). A multivariate prognosis model in the control arm showed thatGleason sum, margin positivity assessed by the review pathologistand post operative PSA value (> 2 ng/ml vs.
Page 1:
CYRURGIE2006
Page 4 and 5:
Heelmeesters allerhande, verenig u!
Page 7:
INHOUDSOPGAVEAbdominale Heelkunde 1
Page 10 and 11:
De resultaten van een grote Noord-A
Page 12 and 13:
VEGF (P = 0.008) correlate with a p
Page 14 and 15:
severe ulcerative ileitis and jejun
Page 16 and 17:
tekens op CT en/of MRI kunnen een b
Page 18 and 19:
data we propose a scoring system in
Page 20 and 21:
ABDOMINALETRANSPLANTATIECHIRURGIECA
Page 22 and 23:
DYCKMANS K., LERUT E., GILLARD P.,
Page 24 and 25:
LERUT J., ORLANDO G., ADAM R., SABB
Page 26 and 27:
histopathologic diagnostic process.
Page 28 and 29:
additional stimulants that the inna
Page 30 and 31:
ARTIKELS UIT HETLEUVENSE NETCREVITS
Page 32 and 33:
PRUYT M., DEVRIENDT D., VANNESTE A.
Page 34 and 35:
BOSHOFF D., BUDTS W., MERTENS L., E
Page 36 and 37:
FLAMENG W., MEURIS B., HERIJGERS P.
Page 38 and 39:
prosthetic valve endocarditis who w
Page 40 and 41:
in these patients We present a case
Page 42 and 43:
SERCA2a. In SKO mice, gene-targeted
Page 44 and 45:
MULTIDISCIPLINAIRBORSTCENTRUMMORALE
Page 46 and 47:
east implant. Only two other cases
Page 48 and 49:
Object: Based on data from primate
Page 50 and 51:
SISCOM hyperperfusion cluster and M
Page 52 and 53:
ONCOLOGISCHEHEELKUNDEBROUNS F., SCH
Page 54 and 55:
infiltrative multilobular spindle c
Page 56 and 57:
multivariable Cox model adjusted fo
Page 58 and 59:
We retrospectively evaluated a surg
Page 60 and 61:
We performed resection arthroplasty
Page 62 and 63:
earing posterior-stabilised. To do
Page 64 and 65:
age and key pinch strength. The dif
Page 66 and 67:
FABRY K., LAMMENS J., DELHEY P., ST
Page 68 and 69:
cases. The mean Knee Society’s kn
Page 70 and 71:
short-term solution for his fractur
Page 72 and 73:
the foot and result in major septic
Page 75 and 76:
SAEGEMAN V., LISMONT D., VERDUYCKT
Page 77 and 78:
Objective: The objective of this st
Page 79 and 80:
VICTOR J., BELLEMANS J.: Physiologi
Page 81 and 82:
skin construct displays authentic f
Page 83 and 84:
Bewertung des Spenderdefektes ergab
Page 85 and 86:
HIERNER R., BERGER A.: Options and
Page 87 and 88:
vascularized ulnar nerve graft and
Page 89 and 90:
cranial bone and dura which cannot
Page 91 and 92:
defects.Adequate debridement, early
Page 93 and 94:
Patients and Methods: Between 1995
Page 95 and 96:
MASSAGE P., VANDENHOF B., VRANCKX J
Page 97 and 98:
Background: High pressure injuries
Page 99 and 100:
VERMEULEN P., DICKENS S., VRANCKX J
Page 101 and 102:
inhibitors that neutralize the impa
Page 103 and 104:
internship. These components repres
Page 105 and 106:
Objective: To evaluate the expressi
Page 107 and 108:
patients were diagnosed with acute
Page 109 and 110:
Conclusions: This study demonstrate
Page 111 and 112: progressive accumulation of FVIII a
Page 113 and 114: his name to this condition through
Page 115 and 116: gevallen, beschouwen wij de minimaa
Page 117 and 118: Table 1Reperfusion time(min)PVR(dyn
Page 119 and 120: transplantation; dehiscence (n = 25
Page 121 and 122: upon reperfusion results from a red
Page 123 and 124: VAN DE WAUWER C., VAN RAEMDONCK D.E
Page 125 and 126: Bronchiolitis obliterans syndrome (
Page 127 and 128: noodzakelijk een beter inzicht te v
Page 129 and 130: patients of 70 years and older trea
Page 131 and 132: of debate. A good pain relief can b
Page 133 and 134: VAN GESTEL L., NIJS S., BROOS P.: T
Page 135 and 136: UROLOGIEALBERSEN M., JONIAU S., VAN
Page 137 and 138: children achieve bladder and bowel
Page 139 and 140: Results: Ninety-five percent of the
Page 141 and 142: esistant to degradation, but at 365
Page 143 and 144: Results: Although the surgery was m
Page 145 and 146: DE RIDDER D.: Conservatieve aanpak
Page 147 and 148: pressures were measured. The effect
Page 149 and 150: GOEMAN L., JONIAU S., OYEN R., VAN
Page 151 and 152: pelvic lymph node status were not w
Page 153 and 154: literature on nephron-sparing surge
Page 155 and 156: on overall survival was studied. Su
Page 157 and 158: materials, although it was architec
Page 159 and 160: Material und Methoden: Von 13 Zentr
Page 161: a remarkable higher number of forei
Page 165 and 166: VANDE WALLE J.G.J., BOGAERT G.A., M
Page 167 and 168: Introduction & Objectives: Control
Page 169 and 170: VAATHEELKUNDEBLADT O., MALEUX G., H
Page 171 and 172: FOURNEAU I., SABBE T., DAENENS K.,
Page 173 and 174: computed tomography (CT) and magnet
Page 175 and 176: We report an unusual case of a uret
Page 177: during GPIb stimulation, its activa
show all

2006 - UZ Leuven

Create successful ePaper yourself

Delete template?

Save as template?